Brensocatib在不同肾功能程度受试者中的药代动力学研究
本研究为1期、多中心、开放标签研究,纳入28例轻度、中度、重度肾功能不全或肾功能正常受试者,单次口服brensocatib 25 mg后评估药代动力学、安全性和耐受性。结果显示各组间药代动力学参数无显著差异,未报告治疗中出现的不良事件,提示肾功能不全无需调整剂量。
要点
- 单次口服brensocatib 25 mg在肾功能不全受试者中耐受良好。
- 肾功能不全对brensocatib的消除和全身暴露无显著影响。
- 肾功能不全受试者无需调整brensocatib剂量。
核心结论
- 研究数据未显示肾功能不全对brensocatib消除和全身暴露有显著影响,提示肾功能不全受试者无需调整剂量。
研究设计与样本
- 1期、多中心、开放标签研究,28例轻度、中度、重度肾功能不全或肾功能正常受试者单次口服brensocatib 25 mg。
主要发现
- 各组间brensocatib药代动力学参数无显著差异。
- 轻度、中度、重度和正常肾功能组的消除半衰期平均变异系数(CV)分别为37.0(15.3)、42.8(21.7)、36.3(22.9)和39.1(17.8)h。
- 所有组的中位达峰时间均为1 h。
- 回归模型分析未发现所选brensocatib药代动力学参数与eGFR之间存在显著关系。
- 研究期间未报告治疗中出现的不良事件。
关键数值与推荐
- 轻度、中度、重度肾功能不全分别定义为eGFR 60至<90、30至<60和15至<30 mL/min/1.73 m2,正常肾功能定义为eGFR ≥90 mL/min/1.73 m2。
临床怎么用
- 基于本研究数据,肾功能不全患者使用brensocatib时无需进行剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Brensocatib is an oral, selective, competitive and reversible dipeptidyl peptidase 1 inhibitor in development for the treatment of bronchiectasis. This study evaluated the pharmacokinetics (PKs), safety and tolerability of brensocatib in participants with varying degrees of renal impairment and normal renal function. METHODS: In this phase 1, multicentre, open-label study, 28 participants with mild, moderate or severe renal impairment (estimated glomerular filtration rate [eGFR] 60 to <90, 30 to <60 and 15 to <30 mL/min/1.73 m2, respectively) or normal renal function (≥90 mL/min/1.73 m2) received a single oral 25-mg dose of brensocatib. Blood samples were collected to measure brensocatib PKs at predetermined time points over the 14-day study period. PK parameters were derived using noncompartmental methods. RESULTS: Demographic and baseline characteristics were similar across groups. There were no significant differences between groups in brensocatib PK parameters. The mean coefficient of variation (CV) of elimination half-life of brensocatib was 37.0 (15.3), 42.8 (21.7), 36.3 (22.9) and 39.1 (17.8) h for mild, moderate, severe and normal renal function groups, respectively. Single-dose brensocatib was quickly absorbed; all groups had a median time to maximum observed plasma concentration of 1 h. Regression model analyses indicated no significant relationships between selected brensocatib PK parameters and eGFR. No treatment-emergent adverse events were reported during the study. CONCLUSION: Single-dose brensocatib was well tolerated. The study data do not indicate a significant effect of renal impairment on brensocatib elimination and systemic exposure, suggesting that dose adjustment of brensocatib is not necessary in participants with renal impairment. CLINICAL TRIAL REGISTRATION NUMBER: NCT05673603.
引用
- Yeung SA, Stein DS, Marbury TC, et al. The pharmacokinetics of brensocatib in participants with renal impairment following a single oral administration. Br J Clin Pharmacol. 2024. PMID: 39574348. doi:10.1111/bcp.16344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。